Researchers examined data on almost 37,000 smokers hospitalized with
heart disease and found only about 8,300, or 23%, received a
prescription for a smoking-cessation aid during their hospital stay.
“Smoking is a very tough addiction to cure and is the leading cause
of preventable death in the U.S.,” lead study author Dr. Quinn Pack
of Baystate Medical Center in Springfield, Massachusetts, told
Reuters Health by email.
“Hospitalizations are excellent opportunities for change,” he said,
because hospitalized patients are highly motivated to improve their
health, and so “a little extra support in the form of smoking
cessation (drugs) could go a long way.”
Some previous research suggests that smoking-cessation therapy in
the hospital followed by additional help afterwards can
significantly improve the odds that a quitting attempt will succeed,
researchers note in JAMA Internal Medicine, online August 21.
In the current study, however, researchers found wide variation in
how often hospitalized patients got cessation help.
At one hospital, for example, smoking cessation aids were prescribed
in 64% of cases, the study found.
But at more than 40% of hospitals, fewer than 20% of eligible
patients received smoking-cessation medications.
Hospitalized patients were more likely to get help quitting if they
also had chronic lung disease or an alcohol abuse problem.
White people in the study were also more likely to receive cessation
aids than people of color. Prescriptions were also more common for
patients insured by Medicaid than for people with other types of
health benefits.
When patients did get help, the nicotine patch was the most commonly
used option.
Study participants were 68 years old on average, most were male, and
most were hospitalized for a heart attack.
The study wasn’t a controlled experiment designed to prove whether
or how prescribing cessation aids in the hospital might improve the
odds that patients actually quit.
Still, the findings highlight a missed opportunity to help people
quit, said Judith Prochaska, a researcher at Stanford University in
California and president of the Society for Research on Nicotine and
Tobacco.
[to top of second column] |
“Despite the known harms of smoking, treatment of tobacco is not a
standard of care for many U.S. hospitals,” Prochaska, who wasn’t
involved in the study, said by email.
Patients should speak up if cessation help isn’t offered, and they
should seek out support groups or psychotherapy in addition to
prescription medications, said Jean-Francois Etter, a researcher at
the University of Geneva in Switzerland who wasn’t involved in the
study.
“There is strong evidence that smoking cessation support combined
with a smoking cessation prescription is both effective and very
cost-effective,” Etter said by email.
It’s possible, however, that some physicians may not want to add
smoking-cessation drugs on top of other treatments patients are
already getting in the hospital, or because the decision is left to
a counselor who isn’t comfortable prescribing smoking-cessation
drugs for heart patients, said Dr. Neal Benowitz, chief of clinical
pharmacology at the University of California San Francisco.
“Patients should understand that smoking-cessation medications are
safe for cardiac patients,” Benowitz, who wasn’t involved in the
study, said by email. “Quitting smoking is the single most important
thing a smoker can do to improve cardiovascular health.”
In particular, there’s a small risk of an increased heart rate and
elevated blood pressure with nicotine-cessation aids like the patch,
gum and lozenges, said Dr. James Davis, medical director of the Duke
Center for Smoking Cessation in Durham, North Carolina.
“There is good evidence now, however, to support the use of nicotine
replacement in hospitalized cardiac patients,” Davis, who wasn’t
involved in the study, said by email. “In short, the risk of smoking
is so high that most experts feel that the very small risks of using
nicotine replacement is simply worth it because it helps smokers
quit smoking.”
SOURCE: http://bit.ly/2wrttvz
JAMA Int Med 2017.
[© 2017 Thomson Reuters. All rights
reserved.] Copyright 2017 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed. |